| Symbol | ANVS |
|---|---|
| Name | ANNOVIS BIO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1055 WESTLAKES DRIVE,SUITE 300, BERWYN, Pennsylvania, 19312, United States |
| Telephone | +1 610 727-3913 |
| Fax | — |
| — | |
| Website | https://www.annovisbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001477845 |
| Description | Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinsons and Alzheimers diseases and other neurodegenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301. Additional info from NASDAQ: |
2026-05-22 00:11
Director Hoffman Michael B 🟢 acquired 76.3K shares of Annovis Bio, Inc. (ANVS) at $1.90 Transaction Date: May 20, 2026 | Filing ID: 065311
Read more
2026-05-20 20:15
(99% Neutral) ANNOVIS BIO, INC. (ANVS) Announces Clinical Development Update
Read more
2026-05-20 17:12
New Form 424B5 - Annovis Bio, Inc. <b>Filed:</b> 2026-05-20 <b>AccNo:</b> 0001104659-26-064510 <b>Size:</b> 576 KB
Read more
2026-05-20 12:00
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
Read more
2026-05-19 20:06
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
Read more
2026-05-19 18:26
New Form 424B5 - Annovis Bio, Inc. <b>Filed:</b> 2026-05-19 <b>AccNo:</b> 0001104659-26-063959 <b>Size:</b> 579 KB
Read more
2026-05-15 20:00
(30% Negative) ANNOVIS BIO, INC. (ANVS) Reports Q2 2026 Financial Results
Read more
2026-05-15 11:30
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07284784 | A Study of Buntanetap in Participants With PD | Phase2 | Parkinson's Disease (PD) | Recruiting | 2026-01-09 | 2029-11-01 | ClinicalTrials.gov |
| NCT06709014 | A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Partic… | Phase3 | Early Alzheimers Disease | Active_Not_Recruiting | 2025-02-04 | 2028-06-01 | ClinicalTrials.gov |
| NCT05686044 | A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate … | Phase2 | Alzheimer Disease | Completed | 2023-04-01 | 2024-02-13 | ClinicalTrials.gov |
| NCT05357989 | A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared … | Phase3 | Parkinson's Disease, Idiopathic | Completed | 2022-08-03 | 2023-12-04 | ClinicalTrials.gov |
| NCT04524351 | Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Pa… | Phase1 | Alzheimer Disease | Completed | 2020-08-14 | 2022-01-31 | ClinicalTrials.gov |
| NCT02925650 | Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's… | Phase1 | Alzheimer's Disease | Completed | 2017-03-02 | 2021-12-31 | ClinicalTrials.gov |
| NCT01072812 | Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects Wit… | Phase1 | Alzheimer's Disease | Terminated | 2010-02-01 | 2010-07-01 | ClinicalTrials.gov |
Total clinical trials: 7
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| buntanetap/posiphen | Other | Phase PHASE2 | Parkinson's Disease (PD) | RECRUITING | NCT07284784 |
| buntanetap/posiphen | Other | Phase PHASE2 | Parkinson's Disease (PD) | RECRUITING | NCT07284784 |
| buntanetap/posiphen | Other | Phase PHASE2 | Parkinson's Disease (PD) | RECRUITING | NCT07284784 |
| buntanetap/posiphen | Other | Phase PHASE2 | Parkinson's Disease (PD) | RECRUITING | NCT07284784 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | ACTIVE_NOT_RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Posiphen® tartrate capsules | Other | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01072812 |
| Placebo | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT04524351 |
| Posiphen | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT04524351 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02925650 |
| Posiphen | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02925650 |
| Placebo | Other | Phase PHASE3 | Parkinson's Disease, Idiopathic | COMPLETED | NCT05357989 |
| buntanetap/posiphen | Other | Phase PHASE3 | Parkinson's Disease, Idiopathic | COMPLETED | NCT05357989 |
| Placebo | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT05686044 |
| Buntanetap/Posiphen | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT05686044 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE2 | Parkinson's Disease (PD) | RECRUITING | NCT07284784 |
| buntanetap/posiphen | Other | Phase PHASE2 | Parkinson's Disease (PD) | RECRUITING | NCT07284784 |
| buntanetap/posiphen | Other | Phase PHASE2 | Parkinson's Disease (PD) | RECRUITING | NCT07284784 |
| buntanetap/posiphen | Other | Phase PHASE2 | Parkinson's Disease (PD) | RECRUITING | NCT07284784 |
| buntanetap/posiphen | Other | Phase PHASE2 | Parkinson's Disease (PD) | RECRUITING | NCT07284784 |
| buntanetap/posiphen | Other | Phase PHASE2 | Parkinson's Disease (PD) | RECRUITING | NCT07284784 |
| buntanetap/posiphen | Other | Phase PHASE2 | Parkinson's Disease (PD) | RECRUITING | NCT07284784 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Buntanetap/Posiphen | DRUG | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT05686044 |
| buntanetap/posiphen | DRUG | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | DRUG | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Posiphen | DRUG | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT04524351 |
| Posiphen® tartrate capsules | DRUG | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01072812 |
Total products: 103